![]()
Dechra acquires biotechnology company, Gallant Pet, Inc.
PR Newswire
BOSTON, Nov. 17, 2026
Expansion into regenerative medicine is a strategic move to broaden treatment possibilities, address unmet needs and shape the future of veterinary care
BOSTON, Nov. 17, 2026 /PRNewswire/ — Dechra, a global leader in veterinary specialty care, today completed its acquisition of Gallant Pet Inc (Gallant), a U.S.-based animal health biotechnology company pioneering off-the-shelf mesenchymal stromal cell (MSC) therapies for pets. Representing another milestone on Dechra’s transformation journey, the expansion into regenerative medicine has the potential to broaden treatment options for complex conditions, address significant unmet needs and help shape the future of veterinary care through a new therapeutic platform.
These ready-to-use, MSC therapies are designed to work with the body’s natural biological processes. By bringing this first-of-its-kind therapy into the Dechra portfolio, the company is advancing a new therapeutic platform designed to treat chronic and complex conditions in pets.
“This acquisition is a strategic investment in expanding what’s possible in veterinary care,” said Dr. Cathy Knupp, Chief Scientific Officer, Dechra. “By combining our specialty animal health expertise, global reach and established veterinary relationships with Gallant’s scientific innovation and regenerative medicine platform, we’re creating a strong foundation to bring new treatment options to veterinarians and their patients.”
Designed to support multiple therapies across different conditions and species, Gallant’s pipeline creates opportunities for continued innovation and development as well as a platform with the potential to establish regenerative medicine as a valued standard in veterinary practice.
“Gallant was built on a bold idea that we could make regenerative medicine accessible for all pets in need,” said Dr. Linda Black, CEO of Gallant. “Dechra understood that vision from the start. We are thrilled to begin this new chapter as part of Dechra who shares our dedication to science and heart. I’m incredibly proud of the team that got us here, and excited to keep pioneering together.”
The first innovation from the pipeline is anticipated as early as 2027. The transaction has been finalized and both parties have agreed that the terms of the transaction will remain confidential.
About Dechra
Dechra is a global leader in veterinary specialty care, dedicated to making a difference in animal health through purpose-built solutions and trusted partnerships that support veterinarian professionals, pet parents, horse owners, and the animals they care for. Our difference makes a difference. To learn more, visit dechra‐us.com.
About Gallant
Gallant is an animal health biotechnology company creating opportunity in veterinary care with a pipeline of off-the-shelf, ready-to-use stromal cell therapies targeting the root cause of disease in pets. Led by pioneers in veterinary regenerative medicine with deep expertise in development, manufacturing, and commercialization, Gallant is making regenerative medicine accessible — moving beyond symptom management to restoring health at the source. Learn more at www.gallant.com.
Media Contact:
Lauren Dorsch
VP, Corporate Affairs and Commercial Communications, Dechra
913-914-6903
lauren.dorsch@dechra.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/dechra-acquires-biotechnology-company-gallant-pet-inc-302942442.html
SOURCE Dechra
